Sildenafil Citrate Therapy for Oligohydramnios

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this randomized trial is to detect whether or not the use of Sildenafil citrate therapy will increase the amniotic fluid volume expressed in term of amniotic fluid index measured via ultrasound for fetuses of pregnancies complicated by oligohydramnios, and to compare the outcomes of Sildenafil-treated pregnancies with similar pregnancies that will remain Sildenafil-naïve.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Al Hayat National Hospital
• Collaborator: Menoufia University
• Treatments: Citric Acid; Sildenafil Citrate

Criteria

Inclusion Criteria:

Pregnant women will be included if they are of:

1. any age, any parity

2. carrying a singleton pregnancy

3. gestational age (GA) 30 weeks or more (based on the last menstrual period and confirmed by the results of ultrasound or determined through early pregnancy sonography)

4. Amniotic fluid index ≤ 5

5. no pregnancy complications such as preeclampsia, gestational hypertension, or diabetes

6. no prior history of kidney, lung, and heart disease (the use of bolus-fluid therapy is contraindicated in these patients)

7. intact fetal membranes.

Exclusion Criteria:

1. Mothers treated with prostaglandin synthetase inhibitors

2. well established labor

3. evidence of fetal distress (non-reactive non stress test)

4. fetal complications (intrauterine growth retardation or obvious fetal anomalies)